Drug Discovery

As the life science industry faces increasing competition—as well as global regulatory and pricing pressures—outsourcing portions or all of manufacturing is becoming increasingly prevalent....

Currently, almost 60 percent of drugs in development are being created by emerging biotech companies focused on therapies for niche diseases with small patient...

The biomanufacturing industry is currently undergoing a revolution in how it produces biopharmaceutical products. The driving force behind this paradigm shift is known as...

The biomanufacturing industry is currently undergoing a revolution in how it produces biopharmaceutical products. The driving force behind this paradigm shift is known as...

Sponsor: Sartorius Stedim BiotechIn this GEN webinar, sponsored by Sartorius Stedim Biotech, we will hear how application of modern bottle and flask closure technologies in combination with machine automation can compress a cell expansion process map to bring about a low-risk, streamlined workflow with reduced operating costs.

Sponsor: Advanced Cell DiagnosticsIn this GEN webinar, sponsored by Lonza, we will examine initial strategies to optimize the amino acid sequence of biotherapeutic molecules, along with techniques to maximize product quality through expression vector design. One tool, GS piggyBac™, which can help improve expression levels, especially for more complex, next-generation biologics, will be discussed.

Eli Lilly will apply Dicerna Pharmaceuticals’ GalXC™ RNA interference (RNAi) technology platform to discover, develop, and commercialize new treatments based on more than 10...

Sponsor: TriLink BiotechnologiesIn this GEN webinar, sponsored by TriLink Biotechnologies, we will hear about data innovations from seven years of research at Novartis Vaccines on self-amplifying mRNA technology and how this approach could enable the concept of vaccines on demand as a rapid response to a real threat rather that the deployment of strategic stockpiles based on epidemiological predictions of a possible threat.

Sponsor: RedShiftBioIn this GEN webinar, we will discuss some typical workflows used to characterize the properties of vaccines, looking at properties such as particle size, surface charge, aggregation, and protein secondary structure.

Sponsor: Cisbio VIEW NOW Broadcast Date: May 21, 2019 Time: 8:00 am PT, 11:00 am ET, 17:00 CET While the importance of ligand-receptor binding kinetics on drug action is...